Search

Roche Holding AG

Cerrado

Sector Salud

317.2 1.21

Resumen

Variación precio

24h

Actual

Mínimo

317

Máximo

317.2

Métricas clave

By Trading Economics

Ingresos

6.3B

Ventas

31B

P/B

Media del Sector

23.915

73.394

Rentabilidad por dividendo

3.07

Margen de beneficio

20.347

Empleados

103,249

EBITDA

11B

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

3.07%

3.09%

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

237B

Apertura anterior

315.99

Cierre anterior

317.2

Noticias sobre sentimiento de mercado

By Acuity

28%

72%

63 / 393 Clasificación en Healthcare

Roche Holding AG Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

30 ene 2025, 09:36 UTC

Ganancias

Roche Expects Growth to Continue This Year After Sales, Earnings Beat Forecasts -- Update

30 ene 2025, 06:32 UTC

Ganancias

Roche Expects Sales, Earnings Growth After Better-Than-Expected Results

26 nov 2024, 15:27 UTC

Adquisiciones, fusiones, absorciones

Trending: Roche to Buy Poseida Therapeutics for Up to $1.5 Billion

26 nov 2024, 12:07 UTC

Principales Movimientos del Mercado

Poseida Therapeutics Shares Triple on Roche Acquisition Worth Up to $1.5 Billion

26 nov 2024, 08:55 UTC

Adquisiciones, fusiones, absorciones

Roche to Acquire Poseida Therapeutics in a Deal Worth Up to $1.5 Billion -- Update

26 nov 2024, 06:50 UTC

Adquisiciones, fusiones, absorciones

Roche to Acquire Poseida Therapeutics in a Deal Worth Up to $1.5 Billion

13 feb 2025, 11:43 UTC

Charlas de Mercado

Roche's Growth Fueled by Key Drugs, Promising Pipeline -- Market Talk

30 ene 2025, 07:56 UTC

Charlas de Mercado
Ganancias

Roche Delivered Solid Results But Diagnostics' Profitability Disappoints -- Market Talk

30 ene 2025, 06:04 UTC

Ganancias

Roche Expects 2025 EPS Growth in High Single Digit Range at Constant Currency

30 ene 2025, 06:04 UTC

Ganancias

Roche Expects 2025 Sales Increase in Mid Single Digit Range at Constant Currency

30 ene 2025, 06:04 UTC

Ganancias

Roche Issues 2025 View

30 ene 2025, 06:03 UTC

Ganancias

Roche Raises Dividend to CHF9.70 Vs CHF9.60

30 ene 2025, 06:03 UTC

Ganancias

Roche 2024 Core Operating Profit CHF20.82B

30 ene 2025, 06:03 UTC

Ganancias

Roche 2024 Net Pft CHF9.19B

30 ene 2025, 06:02 UTC

Ganancias

Analysts Saw 2024 Core EPS at CHF18.59

30 ene 2025, 06:02 UTC

Ganancias

Roche 2024 Core EPS CHF18.80

30 ene 2025, 06:02 UTC

Ganancias

Roche 2024 Sales EUR60.50B

30 ene 2025, 06:02 UTC

Ganancias

Analysts Saw Roche 2024 Revenue at CHF60.41B

30 ene 2025, 06:01 UTC

Ganancias

Roche 2024 Sales CHFB

28 ene 2025, 10:30 UTC

Principales Noticias

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

28 ene 2025, 07:24 UTC

Charlas de Mercado

Roche's Breast Cancer Drug Extends Life of Patients -- Market Talk

15 ene 2025, 10:22 UTC

Charlas de Mercado

Swiss Companies Pay Record Level of Dividends as Buybacks Fall -- Market Talk

8 ene 2025, 06:15 UTC

Adquisiciones, fusiones, absorciones

Roche: 66.11% of Poseida's Shares Were Validly Tendered in Offer

8 ene 2025, 06:12 UTC

Adquisiciones, fusiones, absorciones

Roche Intends to Complete Acquisition of Poseida Therapeutics Later Wednesday

16 dic 2024, 22:03 UTC

Principales Noticias

Novo's New Deal May End Wegovy Shortages. It Could Reshape the Pharma Industry Along the Way. -- Barrons.com

13 dic 2024, 16:36 UTC

Charlas de Mercado

Swiss Equities an Overweight Pick Next Year -- Market Talk

26 nov 2024, 16:10 UTC

Adquisiciones, fusiones, absorciones

Why This Gene-Therapy Company's Stock Is Rising 228% -- Barrons.com

26 nov 2024, 11:52 UTC

Principales Noticias
Principales Movimientos del Mercado
Adquisiciones, fusiones, absorciones

Poseida Therapeutics Shares Triple on Roche Acquisition Worth Up to $1.5B

26 nov 2024, 06:18 UTC

Adquisiciones, fusiones, absorciones

Roche: Non-Tradeable Contingent Value Right Represents Total Deal Value of Up to Around $1.5B

26 nov 2024, 06:18 UTC

Adquisiciones, fusiones, absorciones

Roche: Transaction Is Expected Closed in 1Q 2025

Roche Holding AG Esperado

Sentimiento

By Acuity

63 / 393 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.